Speedel says study shows aliskiren helps treat hypertension

New York, Nov. 15 - Seedel said a phase 2 clinical research program demonatrated the benefits of aliskiren (SPP100) in the treatment of hypertension.

Results of the nine-week clinical study showed that aliskiren provided patients with significantly greater night-time ambulatory blood pressure measurement reductions when added to irbesartan, an angiotensin receptor blocker. In addition to its greater blood pressure control, aliskiren neutralized the angiotensin receptor blocker-induced compensatory rise in Plasma Renin Activity, a risk factor for end organ damage.

The study, presented Tuesday at the American Heart Association Scientific Sessions 2005 in Dallas, examined the safety, tolerability and effectiveness of lowering blood pressure by combining aliskiren with an angiotensin receptor blocker.

Speedel is a Basel, Switzerland, biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.